Your browser doesn't support javascript.
loading
Maternal and fetal outcomes of primary immune thrombocytopenia during pregnancy: A retrospective study.
Gilmore, K S; McLintock, C.
Afiliación
  • Gilmore KS; National Women's Health, Auckland City Hospital, New Zealand.
  • McLintock C; National Women's Health, Auckland City Hospital, New Zealand.
Obstet Med ; 11(1): 12-16, 2018 Mar.
Article en En | MEDLINE | ID: mdl-29636808
ABSTRACT

OBJECTIVE:

We reviewed outcomes of 52 pregnancies in 45 women with immune thrombocytopenic purpura who delivered at Auckland Hospital with an antenatal platelet count of <100 × 109/L. OUTCOME

MEASURES:

Primary outcomes were maternal platelet count at delivery and treatment response. Secondary outcomes included post-partum haemorrhage (PPH).

RESULTS:

Most women had thrombocytopenia at delivery. Treatment with prednisone was given in 14 (27%) pregnancies with responses considered safe for delivery in 11 pregnancies (79%). Women in eight pregnancies also received intravenous immunoglobulin; in five pregnancies (63%) a platelet response acceptable for delivery was achieved.Seventeen pregnancies (33%) were complicated by a PPH ≥500 mL. Ten pregnancies (19%) were complicated by a PPH ≥1000 mL. PPH was reported in all women with a platelet count <50 × 109/L at delivery.

CONCLUSIONS:

There were no antenatal bleeding complications but PPH was common among women with platelet counts <50 × 109/L at the time of birth.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Observational_studies Idioma: En Revista: Obstet Med Año: 2018 Tipo del documento: Article País de afiliación: Nueva Zelanda

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Observational_studies Idioma: En Revista: Obstet Med Año: 2018 Tipo del documento: Article País de afiliación: Nueva Zelanda